Summary
Twenty-two patients with advanced colorectal cancer (CRC) (12 without prior chemotherapy) and fourteen with pretreated breast cancer (BC) were given mitozolomide (MTZ), IV infusion, every six weeks. The starting dose was 90 mg/m2. When it was well-tolerated, dose escalation was done up to 100–115 mg/m2. Toxicity was mild, limited to thrombocytopenia with a median nadir of 1.27 × 105 (0.20–4.86). No response was observed in these patients. MTZ, according to these schedule and dosage, does not show activity in human CRC and pretreated BC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stevens MFG, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG: Antitumour imidazo-tetrazines 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo (5, 1-D)-1, 2, 3, 5-tetrazin-4 (3H)-one, a novel broad spectrum antitumour agent. J Med Chem 27:196–201, 1984
Fostad O, Aamdal S, Pihl A, Boyd MR: Activity of mitozolomide (NSC 353451), a new imidazotetrazine against xenografts from human melanomas, sarcomas, lung and colon carcinomas. Cancer Res 45:1778–1786, 1985
Horgan CMT, Stevens MFG, Tisdale MJ: Preliminary investigation on the mode of action of CCRG 81010 (M and B 39,565). Br J Cancer 48:132, 1983
Gibson NW, Hickman JA, Erickson LC: DNA crosslinking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl) imidazo (5, 1-D)-1, 2, 3, 5-tetrazin-4 (3H)-one. Cancer Res 44:1772–1775, 1984
Slack JA, Newlands ES, Blackledge G, Goddard C, Brindley CJ, Stevens MFG: Clinical pharmacokinetics of mitozolomide (M & B 39,565, CCRG 81010, NSC 353451), abstract 648. Proc Am Assoc Cancer Res 25:164, 1984
Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MFG: Phase I clinical trial of mitozolomide. Cancer Treat Rep 69:801–805, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herait, P., Rougier, P., Oliveira, J. et al. Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer. Invest New Drugs 6, 323–325 (1988). https://doi.org/10.1007/BF00173652
Issue Date:
DOI: https://doi.org/10.1007/BF00173652